A new phase I clinical trial looks at whether a modified bacterial strain is safe and effective in attacking stubborn, treatment-resistant cancer tumors.
A new phase I clinical trial looks at whether a modified bacterial strain is safe and effective in attacking stubborn, treatment-resistant cancer tumors.